700 Saginaw Drive
109 articles about Revolution Medicines
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.
REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.
Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development
Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.
Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines
Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors